Renaissance Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Renaissance Capital’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-44,363	Closed	-$1.25M	–	102
2021 Q4	$1.25M	Sell	44,363 -7,783	-15%	-$239K	0.32%	63
2021 Q3	$1.77M	Sell	52,146 -74,065	-59%	-$2.68M	0.36%	55
2021 Q2	$5.16M	Buy	126,211 +18,786	+17%	+$730K	0.82%	31
2021 Q1	$4.33M	Sell	107,425 -35,068	-25%	-$1.9M	0.64%	39
2020 Q4	$8.43M	Buy	+142,493	New	+$7.35M	1.15%	26

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Renaissance Capital's ADPT Position: Q1 2022 in Review

Renaissance Capital sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 44,363 shares — an estimated $1.25M sold.

Renaissance Capital first reported a position in ADPT in Q4 2020 and held it in 5 quarters. The position peaked at $8.43M in Q4 2020. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

Renaissance Capital reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
Renaissance Capital sold 44,363 Adaptive Biotechnologies shares in Q1 2022, an estimated $1.25M.
Renaissance Capital first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 5 quarters.
Renaissance Capital's Adaptive Biotechnologies position peaked at $8.43M in Q4 2020.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Renaissance Capital's 13F filing for Q1 2022, filed 12 May 2022.